USPTO serial 97681398
SOLCO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 26, 2024
- Examiner
- KENEALY, NATALIE LANGFORD
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SOLCO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Thomas L. Holt
Thomas L. Holt Perkins Coie LLPP.O. Box 2608Seattle, WA 98111UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Analgesic and muscle relaxant pharmaceutical preparations; antibacterial pharmaceuticals; antimicrobial preservatives for cosmetics and pharmaceuticals; pharmaceutical astringents being astringents for medical purposes; balms for pharmaceutical purposes; cream of tartar for pharmaceutical purposes; creosote for pharmaceutical purposes; dermatological pharmaceutical products; digestives for pharmaceutical purposes; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; ferments for pharmaceutical purposes; inhaled pharmaceutical preparations for the treatment of respiratory disease; injectable pharmaceuticals for treatment of anaphylactic reactions; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; iodine for pharmaceutical purposes; liquorice for pharmaceutical purposes; menthol for pharmaceutical purposes; pharmaceutical antitussive-cold preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations, namely, anticoagulants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for use in urology; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, injectable contraceptives; pharmaceutical preparations for treating allergies; pharmaceutical preparations for treating hypertension; pharmaceutical products for treating respiratory disease and asthma; pharmaceutical products for the treatment of joint disease; plant extracts for medical, veterinary and pharmaceutical purposes; potassium preparations for pharmaceutical purposes; pharmaceutical preparations and substances for weight loss; vitamin and mineral supplements for use as ingredients in the food and pharmaceutical industry; drug delivery agents in the form of coatings for pills for facilitating the delivery of a wide range of pharmaceuticals; biological preparations for the treatment of cancer and autoimmune deficiencies and disorders; pharmaceutical, veterinary and sanitary preparations, namely, conjugates of organic and inorganic chemicals with polypeptides, proteins, artificial polypeptides, artificial proteins produced by genetic engineering and for the treatment of viral and infectious diseases, immune system disorders, cancer, diabetes, cardiovascular diseases, central nervous system disorders and diseases; anti-diabetic pharmaceuticals; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; pharmaceutical preparations for treating skin disorders; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer | ACTIVE | Jun 3, 2009 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Prinston Pharmaceutical Inc.
- Other trademarks owned by Prinston Pharmaceutical Inc.
- Other trademarks owned by Prinston Pharmaceutical Inc.
- Other trademarks in Class 005
- Similar marks named SOLCO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 26, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 26, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 9, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 9, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 20, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 4, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 4, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 4, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 1, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 1, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 1, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 30, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 30, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 30, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 30, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 30, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 7, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 7, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 7, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 30, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 8, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 21, 2022 | NWAP | NEW APPLICATION ENTERED | — |